ERBB2 and rhabdomyosarcoma: Although clinical efficacy of HER2-CAR T cell therapy has been shown in solid tumors such as rhabdomyosarcoma, pancreatic cancer, and biliary tract cancer [48,49], clinical studies in GC with HER2-CAR T cells are ongoing (Table 2).